







HAEMOASSIST: A DIGITAL BRIDGE BETWEEN HAEMOPHILIA PATIENTS AND PHARMACISTS - 5PSQ-109

N. BLAZQUEZ-RAMOS, J.A. ROMERO GARRIDO, C. BILBAO GÓMEZ-MARTINO, C. SOBRINO JIMENEZ, C. JIMENEZ NUNEZ, M.E. IBAÑEZ RONCO, L. CARRASCO CUESTA, S. MALLON GONZALEZ, V.L. COLLADA SÁNCHEZ, A.B. ARANCON PARDO, A. HERRERO AMBROSIO

nuria.blazquez@salud.madrid.org

BACKGROUND

Patients with severe hemophilia will need regular parenteral treatment throughout their lives to restore their hemostasis.

These patients reach a high degree of autonomy and their follow-up can be a challenge for healthcare professionals.

In 2020 our Pharmacy Service offered to 315 patients a mobile application (Haemoassist®) to register their medication administrations specifying whether these were prophylactic or to treat bleeding.

OBJECTIVES


Compare the app usage data published in 2020, with the data obtained in 2022, to know if we are achieving:

- Increase the number of patients using the app.
- Improve the quality of the data entered in the app.


MATERIAL AND METHODS

- Count the number of patients who used the app in 2022.
- Study the degree of concordance between the adherence offered by the app adherence = reported administered doses and that prescribed doses calculated from the Pharmacy Service dispensed doses adherence= prescribed doses
- Check whether all patients who, according to the data collected in the hospital's medical record, had bled and were using the app, had reported these **bleeds** in the app.

We compared these 2022 data with those published in 2020.




RESULTS






The number of patients using the app has been increasing.

The quality of patient-reported data is slowly improving.



In 2022, the median adherence achieved by the 190 patients, according to the app, was 8% and the Interquartile Range:0-57% and according to the Pharmacy Service dispensations was 92% (IR: 77 -99%). The degree of concordance between the two calculation methods was 18%. In 2020, concordance was 9%.



Of the 190 patients using the app in 2022, according to the hospital's medical records 153 of them had a bleeding episode, but 74 reported their bleeds in the app. 48% of patients reported their bleeds in the app in 2022 versus 54% in 2020.



^{*} Nuria Blazquez-Ramos, José A. Romero-Garrido, Luis Gonzalez Del Vall, Hortensia De la Corte-Rodriguez, Alicia Herrero-Ambrosio & E. Carlos Rodriguez-Merchan (2023) Development of a telematic pharmaceutical care app (Haemoassist) for multidisciplinary follow-up of patients with congenital coagulopathies, Expert Review of Hematology, 16:3, 213-226, DOI: 10.1080/17474086.2023.2162497